Akums Drugs and Pharmaceuticals has achieved a major milestone in gastrointestinal therapeutics by securing a 20-year patent for its novel “Dual Release Gastro-resistant Composition”, a breakthrough formulation designed to enhance treatment outcomes for Gastroesophageal Reflux Disease (GERD).
Patent Innovation: “Tablet-in-Tablet” Design
The patented “tablet-in-tablet” technology represents a significant advancement in drug delivery systems. The dual-release mechanism enables controlled and sequential release of the active pharmaceutical ingredients, improving treatment efficacy and providing sustained relief from acid reflux and heartburn — the primary symptoms of GERD.
This innovative formulation ensures better absorption and prolonged therapeutic action, offering patients a more effective and convenient solution for managing the chronic digestive disorder.
Regulatory Milestone
Alongside the patent approval, Akums Drugs has received the Drug Controller General of India (DCGI) approval for this product, clearing the way for its eventual commercialization in India. This dual recognition underscores Akums’ growing research and innovation capabilities in the pharmaceutical industry.
Implications for GERD Management
GERD remains one of the most common gastrointestinal conditions globally, often requiring long-term management. Akums’ new composition could redefine GERD treatment standards by:
- Delivering targeted and sustained medication release
- Enhancing treatment adherence and patient comfort
- Reducing symptom recurrence through improved drug stability and timing
Strategic Significance
This patent not only reinforces Akums Drugs’ commitment to advancing pharmaceutical technology but also positions the company as a key innovator in the GERD treatment market. The development aligns with Akums’ broader strategy to expand its intellectual property portfolio and strengthen its footprint in complex formulation research.
Summary:
Akums Drugs and Pharmaceuticals has been granted a 20-year patent and DCGI approval for its innovative dual-release gastro-resistant composition designed to treat GERD. Featuring a unique tablet-in-tablet design, the formulation offers improved efficacy, targeted delivery, and longer-lasting relief, positioning Akums as a leading innovator in gastrointestinal therapeutics.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing